Semaglutid

Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist sharing roughly 94% sequence homology with native human GLP-1. It is one of the most extensively studied metabolic agents, marketed as Ozempic (type 2 diabetes) and Wegovy (chronic weight management), and is among the few peptides in this category supported by large randomized controlled trials rather than only anecdotal use. Structural modifications, including amino acid substitutions and acylation with a C-18 fatty di-acid chain that promotes albumin binding, give it resistance to DPP-4 degradation and a half-life of roughly one week, enabling once-weekly subcutaneous dosing. An oral tablet formulation also exists. In obesity and overweight populations it has produced clinically meaningful, sustained weight loss in placebo-controlled trials, and in people with established cardiovascular disease it has reduced major adverse cardiovascular events. As a YMYL prescription medication, it should only be used under qualified medical supervision; gray-market "research" supply carries purity, dosing, and safety risks.